KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ: 307750)
South Korea
· Delayed Price · Currency is KRW 4,185.00
+65.00 (1.58%)
Sep 11, 2024, 9:32 AM KST
KUKJEON PHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 133,272 | 121,998 | 103,711 | 85,354 |
| Other Revenue | - | - | - | -0 |
| Revenue | 133,272 | 121,998 | 103,711 | 85,354 |
| Revenue Growth (YoY) | 17.00% | 17.63% | 21.51% | - |
| Cost of Revenue | 109,128 | 96,721 | 84,195 | 67,409 |
| Gross Profit | 24,144 | 25,277 | 19,515 | 17,946 |
| Selling, General & Admin | 14,625 | 12,817 | 11,451 | 8,699 |
| Research & Development | 4,939 | 4,821 | 3,981 | 2,651 |
| Operating Expenses | 20,961 | 18,768 | 16,027 | 11,836 |
| Operating Income | 3,184 | 6,509 | 3,488 | 6,109 |
| Interest Expense | -7,071 | -5,735 | -1,802 | -284.47 |
| Interest & Investment Income | 1,125 | 1,591 | 1,037 | 208.91 |
| Earnings From Equity Investments | 14.66 | 1.15 | 301.09 | - |
| Currency Exchange Gain (Loss) | -797.91 | -253.67 | -1,215 | -869.65 |
| Other Non Operating Income (Expenses) | 5,505 | -391.28 | 9,279 | 196.4 |
| EBT Excluding Unusual Items | 1,959 | 1,722 | 11,089 | 5,360 |
| Gain (Loss) on Sale of Investments | 418.37 | 16.28 | 67.84 | -275.98 |
| Gain (Loss) on Sale of Assets | -8.36 | - | -69.18 | -0 |
| Pretax Income | 2,369 | 1,738 | 11,088 | 5,084 |
| Income Tax Expense | -2,284 | -2,954 | 2,210 | 1,046 |
| Earnings From Continuing Operations | 4,654 | 4,692 | 8,877 | 4,038 |
| Minority Interest in Earnings | 701.1 | 132 | 70.7 | - |
| Net Income | 5,355 | 4,824 | 8,948 | 4,038 |
| Net Income to Common | 5,355 | 4,824 | 8,948 | 4,038 |
| Net Income Growth | -42.97% | -46.09% | 121.59% | - |
| Shares Outstanding (Basic) | 49 | 49 | 49 | 44 |
| Shares Outstanding (Diluted) | 54 | 49 | 51 | 44 |
| Shares Change (YoY) | 5.99% | -4.23% | 16.16% | - |
| EPS (Basic) | 109.12 | 98.31 | 182.35 | 91.54 |
| EPS (Diluted) | 65.19 | 98.00 | 11.35 | 91.00 |
| EPS Growth | 222.03% | 763.36% | -87.53% | - |
| Free Cash Flow | -8,321 | -44,269 | -29,304 | -7,367 |
| Free Cash Flow Per Share | -153.24 | -902.17 | -571.94 | -167.01 |
| Dividend Per Share | 10.000 | 10.000 | - | - |
| Gross Margin | 18.12% | 20.72% | 18.82% | 21.02% |
| Operating Margin | 2.39% | 5.34% | 3.36% | 7.16% |
| Profit Margin | 4.02% | 3.95% | 8.63% | 4.73% |
| Free Cash Flow Margin | -6.24% | -36.29% | -28.26% | -8.63% |
| EBITDA | 7,790 | 9,643 | 4,932 | 7,215 |
| EBITDA Margin | 5.85% | 7.90% | 4.76% | 8.45% |
| D&A For EBITDA | 4,607 | 3,134 | 1,444 | 1,106 |
| EBIT | 3,184 | 6,509 | 3,488 | 6,109 |
| EBIT Margin | 2.39% | 5.34% | 3.36% | 7.16% |
| Effective Tax Rate | - | - | 19.94% | 20.58% |
Source: S&P Capital IQ. Standard template. Financial Sources.